S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.21
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.51
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
SERA · Sera Prognostics, Inc. Class A
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Sera Prognostics Inc (SERA)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$2.06
+0.02
(+1.23%)
● At close: October 19 at 4:00:00 PM EDT
DAY'S RANGE
$2.06
$2.06
$2.06
52-WEEK RANGE
$2.06
$1.56
$3.95
What's happening
- SERA is up 1.23% today, trading at $2.06. — Live quote
- Volume today (100) is well below its 3-month average of 28,360. (Finnhub fundamentals)
- Reports earnings on 2026-11-11, 20 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $-0.18 actual vs. $-0.16 estimated (-13.9%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 4
Buy 5
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (10 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
SERA
-31.19%
vs S&P 500
-43.96%
1-YEAR RETURN
SERA
-39.76%
vs S&P 500
-54.32%
6-MONTH RETURN
SERA
-13.62%
3-MONTH RETURN
SERA
-10.57%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.18
Est. $-0.16
MISS -13.9%
2026-04-26 (Q1 2026)
$-0.17
Est. $-0.17
BEAT +0.0%
2026-01-26 (Q4 2025)
$-0.16
Est. $-0.19
BEAT +17.4%
2025-10-26 (Q3 2025)
$-0.16
Est. $-0.20
BEAT +21.6%
Valuation Measures & Ratios
Enterprise Value4$75.7M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)1144.03
Price / Book71.20
EV4 / Revenue1081.21
EV4 / EBITDA—
Profit Margin-47475.71%
Operating Margin-53282.86%
Return on Equity (ROE8)-46.71%
Return on Assets (ROA9)-34.06%
Avg Volume (3M)28,360
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $95.7M | $98.1M | $148.2M | $140.3M | $150.8M |
| P/E | -2.87 | -3.02 | -4.64 | -4.32 | -4.64 |
| Price/Sales | 1242.93 | 1153.77 | 1482.22 | 1299.09 | 1657.64 |
| Price/Book | 1.61 | 1.45 | 1.80 | 1.59 | 1.59 |
| EV/Revenue | 1185.81 | 1104.66 | 1441.41 | 1252.65 | 1600.17 |
| EV/EBITDA | -2.48 | -2.61 | -4.06 | — | — |
| ROE | -56.24% | -47.98% | -38.90% | -36.79% | -34.30% |
| ROA | -38.50% | -34.69% | -29.56% | -29.02% | -27.50% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short229,723
Change from Prior Settlement+7.40%
% of Float—
Days to Cover (Short Ratio)13.42
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Revenue growth is 76.5% on the provider's reported measure. Finnhub fundamentals ↗
- Latest SEC filing is Form 4, filed 2026-10-13; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Net profit margin is -47475.7%. Finnhub fundamentals ↗
- Trailing 52-week price return is -39.8%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on SERA
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $30.0K | $14.0K | $16.0K | $17.0K | $38.0K | $29.0K | $24.0K | $0 |
| Operating income | -$10.0M | -$9.4M | -$9.0M | -$9.3M | -$9.2M | -$8.9M | -$9.3M | -$9.1M |
| Net income | -$9.1M | -$8.4M | -$7.8M | -$8.0M | -$8.2M | -$7.9M | -$8.3M | -$8.1M |
| EPS (diluted) | $-0.18 | $-0.17 | $-0.16 | $-0.16 | $-0.20 | $-0.24 | $-0.25 | $-0.25 |
| EPS (basic) | $-0.18 | $-0.17 | $-0.16 | $-0.16 | $-0.20 | $-0.24 | $-0.25 | $-0.25 |
| Operating margin | -$33.3K | -$66.9K | -$56.1K | -$54.8K | -$24.3K | -$30.6K | -$38.6K | — |
| Net margin | -$30.5K | -$60.0K | -$48.8K | -$47.3K | -$21.5K | -$27.3K | -$34.6K | — |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $86.7M | $93.5M | $101.9M | $108.1M | $111.8M | $118.2M | $72.6M | $79.0M |
| Total liabilities | $27.4M | $25.9M | $26.5M | $25.9M | $23.6M | $23.4M | $24.8M | $24.4M |
| Stockholders' equity | $59.4M | $67.6M | $75.4M | $82.2M | $88.2M | $94.8M | $47.8M | $54.7M |
| Total current assets | $48.1M | $49.7M | $40.8M | $44.5M | $40.9M | $47.3M | $47.6M | $51.1M |
| Total current liabilities | $24.4M | $23.4M | $24.2M | $23.5M | $23.6M | $23.4M | $24.8M | $24.2M |
| Cash & equivalents | $4.4M | $4.2M | $3.9M | $4.1M | $5.0M | $5.2M | $4.0M | $2.7M |
| Marketable securities (current) | $42.0M | $43.2M | $35.3M | $39.2M | $35.1M | $41.0M | $42.2M | $47.1M |
| Accounts receivable | $10.0K | $11.0K | $12.0K | $14.0K | $17.0K | $25.0K | $34.0K | $79.0K |
| Marketable securities (non-current) | $33.8M | $39.4M | $56.6M | $59.1M | $68.4M | $68.0M | $22.0M | $24.6M |
| Property, plant & equipment | — | — | — | — | — | — | — | — |
| Intangible assets | $888.0K | $881.0K | $910.0K | $939.0K | $968.0K | $997.0K | $1.0M | — |
| Other non-current assets | $2.5M | $2.5M | $2.5M | $2.6M | $435.0K | $588.0K | $737.0K | $1.9M |
| Accounts payable | $1.2M | $767.0K | $862.0K | $1.0M | $1.1M | $1.2M | $2.0M | $1.4M |
| Deferred revenue (current) | $20.3M | $20.3M | $20.3M | $20.3M | $20.2M | $20.2M | $20.2M | $20.2M |
| Common stock & paid-in capital | $4.0K | $4.0K | $4.0K | $4.0K | $4.0K | $4.0K | $3.0K | $3.0K |
| Retained earnings | -$329.3M | -$320.1M | -$311.7M | -$303.8M | -$296.0M | -$288.0M | -$279.8M | -$271.2M |
| Accumulated other comprehensive income (loss) | -$48.0K | $16.0K | $262.0K | $268.0K | $145.0K | $76.0K | $60.0K | $292.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$6.3M | -$8.8M | -$6.1M | -$6.5M | -$5.5M | -$7.6M | -$6.3M | -$7.0M |
| Investing cash flow | $6.4M | $9.0M | $5.9M | $5.2M | $5.2M | -$44.8M | $7.4M | $4.9M |
| Financing cash flow | $140.0K | $20.0K | $93.0K | $373.0K | $18.0K | $53.5M | $234.0K | $117.0K |
| Free cash flow | -$6.3M | -$8.8M | -$6.5M | -$6.6M | -$5.8M | -$7.6M | -$6.3M | -$7.0M |
| Capital expenditures | $16.0K | $8.0K | $330.0K | $112.0K | $281.0K | $3.0K | $8.0K | $26.0K |
| Depreciation & amortization | $191.0K | $193.0K | $244.0K | $243.0K | $237.0K | $216.0K | $211.0K | $201.0K |
| Share-based compensation | $823.0K | $835.0K | $1.0M | $1.3M | $1.3M | $1.5M | $1.6M | $1.7M |
| Deferred income taxes | — | — | $0 | — | — | — | $0 | — |
| Change in accounts receivable | -$1.0K | -$1.0K | -$2.0K | -$3.0K | -$8.0K | -$9.0K | -$45.0K | -$22.0K |
| Change in accounts payable | $811.0K | -$70.0K | -$94.0K | $52.0K | $29.0K | -$996.0K | $382.0K | $115.0K |
| Purchases of investments | $10.7M | $1.0M | $7.8M | $8.0M | $15.3M | $56.6M | $5.5M | $3.8M |
| Sales/maturities of investments | — | — | $0 | $0 | $2.5M | — | $0 | $5.0M |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $81.0K | $77.0K | $306.0K | — | — |
| Operating income | -$36.5M | -$36.6M | -$39.8M | -$45.7M | -$35.4M |
| Net income | -$31.9M | -$32.9M | -$36.2M | -$44.2M | -$35.0M |
| EPS (diluted) | $-0.67 | $-0.99 | $-1.16 | $-1.43 | $-2.33 |
| EPS (basic) | $-0.67 | $-0.99 | $-1.16 | $-1.43 | $-2.33 |
| Operating margin | -$45.1K | -$47.6K | -$13.0K | — | — |
| Net margin | -$39.4K | -$42.7K | -$11.8K | — | — |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $101.9M | $72.6M | $95.4M | $116.3M | $147.0M |
| Total liabilities | $26.5M | $24.8M | $25.3M | $17.4M | $8.5M |
| Stockholders' equity | $75.4M | $47.8M | $70.2M | $98.9M | $138.6M |
| Total current assets | $40.8M | $47.6M | $61.3M | $90.1M | $110.3M |
| Total current liabilities | $24.2M | $24.8M | $24.4M | $15.5M | $8.4M |
| Cash & equivalents | $3.9M | $4.0M | $3.9M | $29.9M | $58.9M |
| Marketable securities (current) | $35.3M | $42.2M | $45.2M | $52.8M | $46.2M |
| Accounts receivable | $12.0K | $34.0K | $160.0K | $113.0K | $27.0K |
| Marketable securities (non-current) | $56.6M | $22.0M | $30.8M | $21.3M | $34.8M |
| Property, plant & equipment | — | — | — | — | $1.8M |
| Intangible assets | $910.0K | $1.0M | $0 | — | — |
| Other non-current assets | $2.5M | $737.0K | $1.3M | $1.8M | $157.0K |
| Accounts payable | $862.0K | $2.0M | $1.0M | $1.5M | $1.2M |
| Deferred revenue (current) | $20.3M | $20.2M | $20.2M | $9.1M | $3.1M |
| Common stock & paid-in capital | $4.0K | $3.0K | $3.0K | $3.0K | $3.0K |
| Retained earnings | -$311.7M | -$279.8M | -$246.9M | -$210.7M | -$166.5M |
| Accumulated other comprehensive income (loss) | $262.0K | $60.0K | -$15.0K | -$981.0K | -$183.0K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$25.6M | -$14.2M | -$27.2M | -$34.6M | -$31.6M |
| Investing cash flow | -$28.5M | $11.7M | $438.0K | $5.6M | -$82.6M |
| Financing cash flow | $54.0M | $2.6M | $752.0K | $5.0K | $159.6M |
| Free cash flow | -$26.3M | -$14.2M | -$27.3M | -$35.4M | -$32.9M |
| Capital expenditures | $726.0K | $56.0K | $128.0K | $791.0K | $1.3M |
| Depreciation & amortization | $940.0K | $833.0K | $900.0K | $756.0K | $659.0K |
| Share-based compensation | $5.1M | $7.0M | $5.3M | $5.1M | $3.1M |
| Deferred income taxes | $0 | $0 | $0 | $0 | $0 |
| Change in accounts receivable | -$22.0K | -$126.0K | $47.0K | $86.0K | $25.0K |
| Change in accounts payable | -$1.0M | $455.0K | -$442.0K | $352.0K | $603.0K |
| Purchases of investments | $87.6M | $35.8M | $54.1M | $48.1M | $82.1M |
| Sales/maturities of investments | $2.5M | $5.0M | — | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding SERA as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-05-29 to 2026-10-12
Recent transactions
- Insiders have net sold 83,723 shares over the last 182 days, across 0 purchases and 14 sales.
- Most recent: Inglis Tiffany Eul Davis (Chief Medical Officer) — Open market sale of 8,024 shares on 2026-10-12.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)83,723 sh(14 txns)
Net Shares-83,723
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Inglis Tiffany Eul Davis | Chief Medical Officer | Open market sale | 2026-10-12 | 8,024 |
| Anderson Dyaarl Lee Jr. | Chief Commercial Officer | Open market sale | 2026-09-10 | 1,800 |
| Lindgardt Zhenya | Chief Executive Officer | Open market sale | 2026-09-10 | 7,022 |
| Jackson Benjamin | General Counsel | Open market sale | 2026-09-10 | 2,190 |
| Gleason Scott | Chief Financial Officer | Grant / award | 2026-08-31 | 117,924 |
| Phillips Joshua | Reporting person | Grant / award | 2026-07-10 | 22,426 |
| Mirza Mansoor Raza | Reporting person | Grant / award | 2026-07-10 | 22,426 |
| Lawrence Sandra AJ | Reporting person | Grant / award | 2026-07-10 | 22,426 |
| Kamdar Kim P. | Reporting person | Grant / award | 2026-07-10 | 22,426 |
| CRITCHFIELD GREGORY C | Reporting person | Grant / award | 2026-07-10 | 22,426 |
| Capone Mark Christopher | Reporting person | Grant / award | 2026-07-10 | 42,404 |
| Barlow Jane F | Reporting person | Grant / award | 2026-07-10 | 22,426 |
| Aerts Austin | Chief Financial Officer | Open market sale | 2026-06-11 | 2,037 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-12 | Inglis Tiffany Eul Davis | Chief Medical Officer | Open market sale | 8,024 | $2.03 |
| 2026-09-10 | Anderson Dyaarl Lee Jr. | Chief Commercial Officer | Open market sale | 1,800 | $2.00 |
| 2026-09-10 | Lindgardt Zhenya | Chief Executive Officer | Open market sale | 7,022 | $2.00 |
| 2026-09-10 | Inglis Tiffany Eul Davis | Chief Medical Officer | Open market sale | 486 | $2.00 |
| 2026-09-10 | Jackson Benjamin | General Counsel | Open market sale | 2,190 | $2.00 |
| 2026-09-08 | Lindgardt Zhenya | Chief Executive Officer | Open market sale | 20,139 | $2.00 |
| 2026-08-31 | Gleason Scott | Chief Financial Officer | Grant / award | 117,924 | $0.00 |
| 2026-07-10 | Phillips Joshua | Reporting person | Grant / award | 22,426 | $0.00 |
| 2026-07-10 | Phillips Joshua | Reporting person | Grant / award | 2,260 | $0.00 |
| 2026-07-10 | Mirza Mansoor Raza | Reporting person | Grant / award | 22,426 | $0.00 |
| 2026-07-10 | Mirza Mansoor Raza | Reporting person | Grant / award | 1,771 | $0.00 |
| 2026-07-10 | Lawrence Sandra AJ | Reporting person | Grant / award | 22,426 | $0.00 |
| 2026-07-10 | Lawrence Sandra AJ | Reporting person | Grant / award | 2,276 | $0.00 |
| 2026-07-10 | Kamdar Kim P. | Reporting person | Grant / award | 22,426 | $0.00 |
| 2026-07-10 | Kamdar Kim P. | Reporting person | Grant / award | 3,421 | $0.00 |
| 2026-07-10 | CRITCHFIELD GREGORY C | Reporting person | Grant / award | 22,426 | $0.00 |
| 2026-07-10 | CRITCHFIELD GREGORY C | Reporting person | Grant / award | 1,594 | $0.00 |
| 2026-07-10 | Capone Mark Christopher | Reporting person | Grant / award | 42,404 | $0.00 |
| 2026-07-10 | Capone Mark Christopher | Reporting person | Grant / award | 1,975 | $0.00 |
| 2026-07-10 | Barlow Jane F | Reporting person | Grant / award | 22,426 | $0.00 |
| 2026-07-10 | Barlow Jane F | Reporting person | Grant / award | 1,949 | $0.00 |
| 2026-06-11 | Anderson Dyaarl Lee Jr. | Chief Commercial Officer | Open market sale | 4,739 | $2.01 |
| 2026-06-11 | Aerts Austin | Chief Financial Officer | Open market sale | 2,037 | $2.01 |
| 2026-06-11 | Lindgardt Zhenya | Chief Executive Officer | Open market sale | 6,990 | $2.01 |
| 2026-06-11 | Inglis Tiffany Eul Davis | Chief Medical Officer | Open market sale | 362 | $2.01 |
| 2026-06-11 | Jackson Benjamin | General Counsel | Open market sale | 2,179 | $2.01 |
| 2026-06-09 | Lindgardt Zhenya | Chief Executive Officer | Open market sale | 20,755 | $2.08 |
| 2026-06-09 | Aerts Austin | Chief Financial Officer | Open market sale | 5,440 | $2.08 |
| 2026-06-08 | Lawrence Sandra AJ | Reporting person | Open market sale | 1,560 | $2.15 |
| 2026-05-29 | Jackson Benjamin | General Counsel | Grant / award | 5,000 | $1.84 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-21 23:34 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-13 | 4 | 2026-10-12 | View on SEC.gov → |
| 2026-09-11 | 4 | 2026-09-10 | View on SEC.gov → |
| 2026-09-11 | 4 | 2026-09-10 | View on SEC.gov → |
| 2026-09-11 | 4 | 2026-09-10 | View on SEC.gov → |
| 2026-09-11 | 4 | 2026-09-10 | View on SEC.gov → |
| 2026-09-09 | 4 | 2026-09-08 | View on SEC.gov → |
| 2026-09-02 | 4 | 2026-08-31 | View on SEC.gov → |
| 2026-09-01 | 4 | 2026-08-31 | View on SEC.gov → |
| 2026-08-19 | 8-K | 2026-08-14 | View on SEC.gov → |
| 2026-08-12 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-12 | 8-K | 2026-08-12 | View on SEC.gov → |
| 2026-07-14 | 4 | 2026-07-10 | View on SEC.gov → |
Recent news
Headlines about SERA (Sera Prognostics, Inc. Class A). Links open the publisher — we don’t host full articles.
-
SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF THIRD QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON NOVEMBER 4, 2026
Yahoo · 2026-10-21 -
“If the US Can’t Stop Putin, Let Them Give Us Anti-Missile Systems to Protect Our Energy Infrastructure,” — Zelenskyy in an Interview with Corriere della Sera
uatv.ua · 2026-10-20 -
On the 20th, Seragem announced that its founder, Chairman Lee Hwan-sung, adopted CEO Lee Kyung-soo
매일경제 · 2026-10-20 -
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 2026-10-19 -
Xurrent Extends Sera AI Into an AI SRE teammate to Help Engineering Teams Resolve Incidents Faster
Yahoo Finance · 2026-10-15 -
Sera Prognostics Q3 2026 Earnings Date and Estimates
MarketBeat · 2026-10-15 -
1 in 10 U.S. Babies Are Born Too Early. A Leading OB-GYN Says Most Mothers Can Learn Their Risk by Week 21, and Do Something About It.
Yahoo Finance · 2026-08-25 -
Sera (SERA) Q2 2026 Earnings Call Transcript
Yahoo Finance · 2026-08-19
No headlines in this category right now — try “All”.